SITAGLIPTINE/CHLORHYDRATE DE METFORMINE MYLAN 50 mg/1000 mg, film-coated tablet 60 tablets
Active ingredients: Metformin hydrochloride, Sitagliptin hydrochloride monohydrate, Sitagliptin
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SITAGLIPTINE/CHLORHYDRATE DE METFORMINE MYLAN 50 mg/1000 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 60 plaquettes PVC polyéthylène PVDC aluminium de 1 comprimé (dose unitaire)
- Marketing authorisation holder
- MYLAN PHARMACEUTICALS (IRLANDE)
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Jul 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62024905CIP73025080CIP133400930250808Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SITAGLIPTINEcomprimé | 50 mg · un comprimé | FT |
| CHLORHYDRATE DE METFORMINEcomprimé | 1000 mg · un comprimé | SA |
| CHLORHYDRATE DE SITAGLIPTINE MONOHYDRATÉcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.